Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro

被引:142
作者
Audran, R
Peter, K
Dannull, J
Men, Y
Scandella, E
Groettrup, M
Gander, B
Corradin, G
机构
[1] Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland
[2] Cantonal Hosp St Gallen, Dept Res, St Gallen, Switzerland
[3] Swiss Fed Inst Technol, Inst Pharmaceut Sci, Zurich, Switzerland
关键词
biodegradable microspheres; poly; (D; L-lactide-co-glycolide); CTL peptides; dendritic cells; macrophages;
D O I
10.1016/S0264-410X(02)00521-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Biodegradable microspheres (MS) consisting of poly(D,L-lactide-co-glycolide) (PLGA) represent a promising alternative to conventional adjuvants. The adjustable pulsatile release of encapsulated material from such MS offers the potential to mimic the priming and boosting injections of conventional immunization regimens. In this paper, we demonstrate that MS can serve as antigen reservoirs in antigen presenting cells (APC), so that antigen is presented for extended periods of time (up to 9 days). In particular, we could show by measurement of IFN-gamma production that encapsulated peptides were presented to cytotoxic T lymphocytes (CTL) by mouse and human macrophages as well as by human dendritic cells in vitro for a longer time period as compared to soluble peptides. The extended antigen presentation may thus improve the CTL response in vivo. These results may be of paramount importance in cancer vaccination therapy since MS may serve as antigen reservoirs to extend the presentation time by APC used to boost the patient's immune response to tumor antigens. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1250 / 1255
页数:6
相关论文
共 21 条
[1]   BIODEGRADABLE MICROSPHERES AS CONTROLLED-RELEASE TETANUS TOXOID DELIVERY SYSTEMS [J].
ALONSO, MJ ;
GUPTA, RK ;
MIN, C ;
SIBER, GR ;
LANGER, R .
VACCINE, 1994, 12 (04) :299-306
[2]   Enhanced immunogenicity of microencapsulated tetanus toxoid with stabilizing agents [J].
Audran, R ;
Men, Y ;
Johansen, P ;
Gander, B ;
Corradin, G .
PHARMACEUTICAL RESEARCH, 1998, 15 (07) :1111-1116
[3]   Dendritic cells as vectors for therapy [J].
Banchereau, J ;
Schuler-Thurner, B ;
Palucka, AK ;
Schuler, G .
CELL, 2001, 106 (03) :271-274
[4]  
BEDNAREK MA, 1991, J IMMUNOL, V147, P4047
[5]  
BLUMTIROUVANZIAM U, 1995, J IMMUNOL, V154, P3922
[6]  
COICO R, CURRENT PROTOCOLS
[7]   The functional half-life of H-2K(d)-restricted T cell epitopes on living cells [J].
Eberl, G ;
Widmann, C ;
Corradin, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (09) :1993-1999
[8]   BIODEGRADABLE AND BIOCOMPATIBLE POLY(DL-LACTIDE-CO-GLYCOLIDE) MICROSPHERES AS AN ADJUVANT FOR STAPHYLOCOCCAL ENTEROTOXIN-B TOXOID WHICH ENHANCES THE LEVEL OF TOXIN-NEUTRALIZING ANTIBODIES [J].
ELDRIDGE, JH ;
STAAS, JK ;
MEULBROEK, JA ;
TICE, TR ;
GILLEY, RM .
INFECTION AND IMMUNITY, 1991, 59 (09) :2978-2986
[9]  
Haegel-Kronenberger H, 1998, J IMMUNOL, V161, P3902
[10]   PROTECTION OF MICE FROM BORDETELLA-PERTUSSIS RESPIRATORY-INFECTION USING MICROENCAPSULATED PERTUSSIS FIMBRIAE [J].
JONES, DH ;
MCBRIDE, BW ;
JEFFERY, H ;
OHAGAN, DT ;
ROBINSON, A ;
FARRAR, GH .
VACCINE, 1995, 13 (07) :675-681